152 related articles for article (PubMed ID: 29890238)
1. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.
van Anrooij B; Oude Elberink JNG; Span LFR; de Monchy JGR; Rosati S; Mulder AB; Kluin-Nelemans JC
J Allergy Clin Immunol; 2018 Sep; 142(3):1006-1008.e7. PubMed ID: 29890238
[No Abstract] [Full Text] [Related]
2. Midostaurin (Rydapt) for AML and advanced systemic mastocytosis.
Med Lett Drugs Ther; 2017 Aug; 59(1527):e140. PubMed ID: 28787746
[No Abstract] [Full Text] [Related]
3. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience.
Farrukh F; Gangat N; Shah MV; Litzow MR; Elliott MA; Begna K; Hook CC; Tefferi A; Pardanani A
Am J Hematol; 2022 Apr; 97(4):E138-E140. PubMed ID: 35015315
[No Abstract] [Full Text] [Related]
9. Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant.
Martynova A; Nael A; O Neill C; Ramsingh G; Merchant A; Yaghmour B; Yaghmour G
Br J Haematol; 2019 Sep; 186(5):e139-e141. PubMed ID: 31111479
[No Abstract] [Full Text] [Related]
10. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
11. Midostaurin in Advanced Systemic Mastocytosis.
Chandesris MO; Damaj G; Canioni D; Brouzes C; Lhermitte L; Hanssens K; Frenzel L; Cherquaoui Z; Durieu I; Durupt S; Gyan E; Beyne-Rauzy O; Launay D; Faure C; Hamidou M; Besnard S; Diouf M; Schiffmann A; Niault M; Jeandel PY; Ranta D; Gressin R; Chantepie S; Barete S; Dubreuil P; Bourget P; Lortholary O; Hermine O;
N Engl J Med; 2016 Jun; 374(26):2605-7. PubMed ID: 27355555
[No Abstract] [Full Text] [Related]
12. Treatment of systemic mastocytosis in an infant with midostaurin.
Liu MM; Kohn LA; Roach GD; Sun G; Garcia-Lloret MI; Butte MJ
J Allergy Clin Immunol Pract; 2019; 7(8):2929-2931.e1. PubMed ID: 31154031
[No Abstract] [Full Text] [Related]
13. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
Schlenk RF; Kayser S
Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin-induced lichenoid photoallergic reaction in a patient with systemic mastocytosis.
Cura P; Salomon G; Bulai Livideanu C; Tournier E; Godillot C; Casassa E; Sévérino-Freire M; Paul C; Marguery MC
Photodermatol Photoimmunol Photomed; 2022 Sep; 38(5):511-513. PubMed ID: 35103335
[No Abstract] [Full Text] [Related]
17. A Granular Approach to a Patient with Diarrhea and Flushing.
Gremida A; Mir F; McCarthy D
Dig Dis Sci; 2019 Jul; 64(7):1792-1797. PubMed ID: 31111279
[No Abstract] [Full Text] [Related]
18. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
20. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
